Genzyme Corporation v. Dr. Reddy's Laboratories, Ltd, No. 16-2206 (Fed. Cir. Dec. 18, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This consolidated set of appeal s arises from a Hatch - Waxman action brought by Genzyme Corporation and Sanofi-Aventis U.S. LLC (collectively, Genzyme) against Dr. Reddy’s Laboratories, Ltd., Dr. Reddy’s Laboratories, Inc., and Teva Pharmaceuticals USA, Inc. (collect ively, DRL). After a bench trial, the district court held, inter alia, that DRL failed to prove that claim 19 of U.S. Patent No. 7,897,590 (the ’590 Patent) is invalid for obviousness. We affirm.